Hiroshi Takahashi, Masashi Yamazaki, Akihiko Okawa, Masao Koda, Masayuki Hashimoto, Mitsuhiro Hashimoto, Koichi Hayashi, Tsuyoshi Sakuma, Junko Kawabe, Takayuki Fujiyoshi, Takeo Furuya, Tomonori Yamauchi, Ryo Kadota, Tomohiro Miyashita, Chikato Mannoji, Yukio Someya, Yutaka Nishio, Takahito Kamada, Shuhei Koshizuka, Osamu Ikeda, Tsuneji Kita, Yasuchika Aoki, Katsunori Yoshinaga, Atsushi Murata, Kazuhisa Takahashi
Chiba Medical Journal 86(5) 175-183 2010年
We have started a Phase I and IIa clinical trial to assess the safety and feasibility of neuroprotective therapy using granulocyte colony-stimulating factor (G-CSF) for patients with acute spinal cord injury (SCI). Six patients with acute SCI were received intravenous G-CSF injection (5μg/kg per day) for 5 days. After injection, we had neurological evaluations with American Spinal Cord Injury Association (ASIA) score, and confirmed side effects for medication with physical findings and laboratory data. In all 6 patients, some neurological improvement was obtained after medication. Mean white blood cell (WBC) counts were 25.2 to 38.4 (&
times
103/μl) 1 days after medication
that was higher than previous counts. From 1 day to 5 days after the medication, during the administration, WBC counts kept higher than previous counts, and 1 days after the end of medication, WBC counts returned to the previous rate. No severe adverse effects were seen in all patients after G-CSF injection.